Recombinant Human Ceramide synthase 5 (CERS5)

What is the primary function of CERS5 in cellular metabolism?

CERS5 is an essential enzyme that maintains cellular C16:0 sphingolipid pools in multiple tissues including lung, spleen, muscle, liver, and white adipose tissue. It specifically catalyzes the N-acylation of sphingoid bases using C16:0-CoA as a substrate, thereby contributing to ceramide synthesis with specific acyl chain lengths. The substrate specificity for C16:0-CoA is determined within a 150-amino acid region of the TLC domain . CERS5 plays a crucial role in cellular sphingolipid homeostasis, which impacts membrane integrity, cell signaling pathways, and stress responses.

How does CERS5 interact with other ceramide synthases?

CERS5 forms both homodimers and heterodimers with other ceramide synthases. It has been demonstrated that CERS5 dimerizes with CERS2 and enhances CERS2 activity . This interaction between different ceramide synthases may provide a molecular mechanism for regulating the acyl chain composition of ceramides in various tissues. Experimental evidence suggests that dimerization modulates enzymatic activity, and co-expression studies demonstrate that catalytically inactive CERS5 mutants can act in a dominant-negative fashion to inhibit the activity of full-length CERS5 .

What are the optimal expression systems for studying recombinant CERS5?

When designing experiments with recombinant CERS5, researchers typically use mammalian expression systems such as HEK cells, as these maintain appropriate post-translational modifications and membrane targeting. Based on published methodologies, CERS5 constructs can be effectively expressed using vectors like PCMV with appropriate epitope tags (HA, FLAG) for detection and immunoprecipitation . When planning co-expression studies, it's advisable to use different epitope tags for each construct to facilitate separate identification and co-immunoprecipitation experiments. Transfection efficiency should be monitored and standardized to ensure consistent CERS5 expression levels across experimental replicates.

How should CERS5 knockout models be designed and validated?

The generation of CERS5 knockout models requires careful design and validation. Based on previous successful approaches, one effective strategy involves replacing the complete coding sequence with a reporter gene (such as NLS-lacZ) and a selectable marker (like a frt-flanked neomycin resistance gene). The targeting vector should contain homology arms flanking the coding sequence for proper homologous recombination .

Validation of CERS5 knockout models should include:

• PCR screening for correct homologous recombination

• Southern blotting to confirm targeting vector integration

• Western blotting using specific antibodies to confirm absence of CERS5 protein

• Lipidomic analysis to verify altered sphingolipid profiles, particularly decreased C16:0-ceramide levels in relevant tissues

What controls are essential when studying CERS5 dimerization and its effects on enzymatic activity?

When investigating CERS5 dimerization and its effects on enzymatic activity, several controls are crucial:

• Expression level controls: Maintain consistent expression levels of all constructs, verified by Western blotting

• Activity controls: Include wild-type CERS5 alone to establish baseline enzymatic activity

• Interaction controls: Use catalytically inactive mutants (such as CERS5 ΔC332–392) to distinguish between dimerization and activity effects

• Specificity controls: Test interaction with non-CerS membrane proteins to confirm specificity of observed interactions

• Quantitative controls: Establish dose-dependency by transfecting increasing amounts of interaction partners

These controls help distinguish between effects on protein stability, localization, and intrinsic enzymatic activity when interpreting results from co-expression studies.

How is CERS5 expression altered in cancer, and what are the implications for patient prognosis?

CERS5 expression is significantly altered in several cancer types, with important implications for patient prognosis. In gastric cancer, CerS5 is consistently overexpressed in primary tumor tissues and metastatic lymph nodes compared to normal tissues . High expression of CERS5 is significantly correlated with poor prognosis in gastric cancer patients, particularly in Asian populations. The 5-year survival rate for patients with high CerS5 expression (32.8%) is considerably lower than for those with low expression (52.8%) .

Similar patterns have been observed in other cancers:

• Colorectal cancer shows upregulated CERS5 mRNA expression

• Neuroglioma tissues exhibit significantly higher CERS5 levels than normal nervous ganglion tissues

• Endometrial cancer demonstrates overexpression of CERS5 mRNA

Multivariate analysis confirms CERS5 expression as an independent prognostic factor in gastric cancer, alongside other clinicopathological features such as Lauren classification, N stage, M stage, and CA125 levels .

What is the relationship between CERS5 expression and clinicopathological features in cancer patients?

The relationship between CERS5 expression and clinicopathological features has been most thoroughly investigated in gastric cancer. Statistical analyses reveal significant correlations between CERS5 expression levels and:

Interestingly, while CERS5 expression is a significant prognostic factor in Asian populations (both in direct studies and ACRG database), this correlation was not observed in the TCGA database, which primarily contains data from European populations. This suggests potential ethnic or population-specific effects of CERS5 in cancer progression .

How does CERS5 affect response to therapy in cancer models?

CERS5 plays a significant role in modulating cellular responses to therapeutic interventions. In cancer models, CERS5 has been implicated in:

• Radiation response: CERS5 regulates post-mitochondrial events during apoptosis in response to UV radiation, working cooperatively with CERS6. It increases apoptosis in response to ionizing radiation in cancer cell lines .

• Chemotherapy sensitivity: Knockdown of CERS5 using specific shRNA inhibits autophagy and increases drug sensitivity of colorectal cancer cells to chemotherapeutics like oxaliplatin and 5-FU .

• Ceramide-mediated apoptosis: CERS5 and CERS6 together are responsible for radiation-induced C16:0-ceramide production in mitochondrion-associated endoplasmic reticulum membranes, eventually leading to mitochondrial ceramide accumulation and cell death .

These findings suggest that CERS5 could be a potential therapeutic target, particularly in cancers where its expression is elevated. Modulating CERS5 activity might enhance the efficacy of existing cancer treatments.

What are the most effective methods for measuring CERS5 enzymatic activity?

When measuring CERS5 enzymatic activity, researchers should consider several methodological approaches based on experimental objectives:

For cell-free assays:

• Use microsomal preparations from cells expressing recombinant CERS5

• Include appropriate sphingoid base substrate (typically sphinganine)

• Supply acyl-CoA donor (preferably C16:0-CoA for CERS5)

• Incorporate radioactive or fluorescent labels for product detection

• Include proper negative controls (heat-inactivated enzyme, competitive inhibitors)

For cellular assays:

• Transfect cells with CERS5 expression constructs

• Supply cell-permeable sphingoid base precursors

• Analyze ceramide production using mass spectrometry or TLC

• Compare results with CerS5-knockout or knockdown controls

Quantification methods should include liquid chromatography tandem-mass spectrometry (LC-MS/MS) for precise measurement of specific ceramide species. This approach has been effectively used to quantify ceramide levels in various tissue samples, including cancer tissues .

How can researchers effectively distinguish between the activities of different ceramide synthases in complex biological samples?

Distinguishing between different ceramide synthases in complex biological samples presents a significant challenge due to overlapping substrate preferences. A comprehensive approach includes:

• Acyl-CoA specificity profiling: CERS5 preferentially utilizes C16:0-CoA, while other CerS family members have different chain length preferences (e.g., CERS2 prefers very-long-chain acyl-CoAs).

• Selective inhibition: Use selective inhibitors or competitive substrates that differentially affect CerS isoforms.

• Genetic approaches: Implement selective knockdown or knockout of specific CerS family members, followed by comprehensive lipidomic analysis to identify changes in specific ceramide species.

• Expression correlation: Correlate enzyme activity with protein expression levels using isoform-specific antibodies.

• Heterologous expression: Express individual recombinant CerS enzymes in systems lacking endogenous ceramide synthase activity to establish baseline activities and substrate preferences.

This multifaceted approach allows researchers to attribute observed changes in ceramide profiles to specific CerS isoforms, particularly in tissues expressing multiple CerS family members .

What technical considerations are important when analyzing CERS5 protein-protein interactions?

When analyzing CERS5 protein-protein interactions, several technical considerations are crucial:

Research demonstrates that CERS5 forms functionally relevant homo- and heterodimers, and appropriate technical approaches are essential for accurately characterizing these interactions .

What are the emerging roles of CERS5 in metabolic disorders?

Recent investigations have uncovered potential roles for CERS5 in metabolic disorders, particularly related to obesity and insulin resistance. CERS5 knockout mice have been used to study the effect of CERS5 deficiency on the development of obesity and insulin resistance after high-fat diet challenges . These studies suggest that altered C16:0 sphingolipid pools in tissues like white adipose tissue, liver, and muscle may influence metabolic pathways related to lipid storage, glucose tolerance, and insulin sensitivity.

The role of CERS5 in maintaining specific ceramide pools in metabolically active tissues suggests it may be a potential therapeutic target in metabolic disorders. Research is ongoing to determine whether selective inhibition of CERS5 could provide metabolic benefits without disrupting essential cellular functions.

How do CERS5 genetic variants influence enzyme function and disease susceptibility?

While comprehensive studies on CERS5 genetic variants are still emerging, structural and functional studies provide insights into how variations might impact enzyme function:

• Variants affecting the TLC domain (especially within the 150-amino acid region determining substrate specificity) may alter the acyl-CoA chain length preference, potentially shifting the ceramide profile.

• Mutations in the regions encoding the two positively charged amino acids after the homeodomain would likely impair catalytic activity, as these residues are essential for enzymatic function .

• Variants affecting the C-terminal transmembrane domain could disrupt proper membrane integration or protein folding, potentially creating dominant-negative effects as observed with truncated CERS5 constructs .

Future genome-wide association studies may reveal specific CERS5 variants associated with disease susceptibility, particularly in conditions where ceramide metabolism is implicated, such as cancer, metabolic disorders, and neurodegenerative diseases.

What are the current contradictions or knowledge gaps in CERS5 research that require further investigation?

Several significant knowledge gaps and contradictions in CERS5 research warrant further investigation:

• Population-specific effects: The discrepancy between CERS5 prognostic value in Asian (ACRG database) versus European (TCGA database) gastric cancer populations requires clarification. This suggests potential ethnic variations in CERS5 biology or interactions with genetic or environmental factors .

• Dual roles in cancer: CERS5 appears to have context-dependent effects in cancer. It promotes apoptosis in response to radiation and hypoxia/reoxygenation, yet its overexpression correlates with poor prognosis in several cancers . This apparent contradiction requires mechanistic clarification.

• Regulatory mechanisms: The transcriptional, post-transcriptional, and post-translational mechanisms regulating CERS5 expression and activity remain poorly understood.

• Precise subcellular localization: While CERS5 operates in the ER, its precise localization to specific ER subdomains and potential translocation under stress conditions requires further investigation.

• Comprehensive in vivo characterization: Despite extensive biochemical characterization and knockdown studies, comprehensive in vivo characterization of CERS5 function in various physiological and pathological contexts remains incomplete .

Addressing these knowledge gaps will provide a more complete understanding of CERS5 biology and its potential as a therapeutic target in various diseases.